CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 45 enrolled
Drug / intervention
Clotild® Smart Guidewire System (CSGS)device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04993079
NCT04993079N/ACompleted

Clotild® Smart Guidewire System Evaluation in Endovascular Thrombectomy Procedure

Sensome·interventional·Posted Aug 6, 2021·Updated Feb 27, 2026

In Brief

A clinical study evaluating Clotild® Smart Guidewire System (CSGS) for Stroke. Completed, enrolled 45 participants across 3 sites in 2 countries.

Detailed Summary

The purpose of this First-in-Human study is to evaluate the safety of using the Clotild® system to guide the endovascular thrombectomy (EVT) device to the clot location during EVT for the treatment of an acute ischemic stroke eligible to EVT, whatever the EVT device chosen. A secondary purpose is to assess the clinical performance, defined as the feasibility of measuring clot electrophysiological parameters in vivo during EVT procedures.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStroke
CountriesAustralia, France
Collaborators--

Timeline

N/ACompletedFinished
20222023202420252026
First PostedAug 6, 2021
Enrollment StartAug 26, 2021
Primary CompletionApr 13, 2024
Study CompletionApr 16, 2024
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 4.9 years ago

Interventions

Clotild® Smart Guidewire System (CSGS)device

Use of Clotild® Smart Guidewire System as neurovascular guidewire